UroGen Pharma Ltd. (URGN) — SEC Filings

Latest SEC filings for UroGen Pharma Ltd. (URGN), explained in plain English.

Sentiment Overview: 4 bullish, 1 bearish, 44 neutral, 1 mixed

Recent Filings (50)

• UroGen Pharma's Losses Widen Amid Soaring Expenses, Cash Drains — 10-Q · 2025-11-06T00:00:00.000Z [bearish] Risk: high
  UroGen Pharma Ltd. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $127.1 million, up from $89.4 million in t
• UroGen Pharma Ltd. Announces Executive and Board Changes — 8-K · 2025-08-27T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. announced on August 26, 2025, several key executive and board changes. The company elected new directors and appointed new officers, alongsid
• UroGen Pharma Corrects Q2 2024 EPS, Adjusts Prepaid Obligations — 10-Q · 2025-08-07T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. (URGN) filed its 10-Q for the period ending June 30, 2025, revealing an immaterial correction to its previously reported loss per share for Q
• UroGen Pharma Details Executive Equity Awards Ahead of Shareholder Vote — DEF 14A · 2025-07-15T00:00:00.000Z [mixed] Risk: medium
  UroGen Pharma Ltd.'s DEF 14A filing, dated July 15, 2025, primarily focuses on executive compensation and governance matters for the fiscal year ended December
• UroGen Pharma Ltd. Reports Board and Executive Changes — 8-K · 2025-07-03T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. announced on June 30, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the depa
• Deciphera to Acquire UroGen Pharma for $750M — 8-K · 2025-06-13T00:00:00.000Z [bullish] Risk: medium
  UroGen Pharma Ltd. announced on June 12, 2025, that it has entered into a definitive agreement to be acquired by Deciphera Pharmaceuticals, LLC. The transaction
• UroGen Pharma Q1 2025: $100M Assets, $8.8M Net Loss — 10-Q · 2025-05-12T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. filed its Q1 2025 10-Q report on May 12, 2025, for the period ending March 31, 2025. The company reported total assets of $100 million and to
• UroGen Pharma Files 2024 Annual Report Amendment — 10-K/A · 2025-04-30T00:00:00.000Z [neutral] Risk: low
  UroGen Pharma Ltd. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated April 30, 2025, provides upda
• UroGen Pharma Ltd. Files 2024 10-K — 10-K · 2025-03-10T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. filed its 2024 10-K on March 10, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company's total
• UroGen Pharma Ltd. Files 8-K: Material Agreement & Equity Sales — 8-K · 2025-02-20T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. announced on February 14, 2025, that it entered into a material definitive agreement and also reported unregistered sales of equity securitie
• UroGen Pharma Files 8-K — 8-K · 2025-01-14T00:00:00.000Z [neutral] Risk: low
  UroGen Pharma Ltd. filed an 8-K on January 14, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spe
• Pontifax Amends UroGen Pharma Holdings Filing — SC 13D/A · 2024-11-18T00:00:00.000Z [neutral] Risk: low
  Pontifax Management III G.P. (2011) Ltd. filed an amendment to its Schedule 13D on November 18, 2024, regarding its holdings in UroGen Pharma Ltd. The filing in
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-13T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-11-08T00:00:00.000Z [neutral]
• UroGen Pharma Files 8-K on Financials — 8-K · 2024-11-06T00:00:00.000Z [neutral] Risk: low
  UroGen Pharma Ltd. filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statements an
• UroGen Pharma Q3 2024: Assets $42.2M, Liabilities $32.5M — 10-Q · 2024-11-06T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $42.2 million and total liabilities of $32.5 mi
• SC 13G Filing — SC 13G · 2024-11-06T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-10-24T00:00:00.000Z [neutral]
• UroGen Pharma Appoints New CMO, Elects Directors — 8-K · 2024-10-09T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. announced on October 7, 2024, the appointment of Dr. Anup Rampersaud as Chief Medical Officer and the election of Ms. Sarah O'Connor and Mr.
• UroGen Pharma Ltd. Reports New Financial Obligation — 8-K · 2024-09-24T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. reported on September 23, 2024, that it has entered into a direct financial obligation. The filing does not specify the exact nature or amoun
• UroGen Pharma Appoints New CMO and Board Member — 8-K · 2024-09-13T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. announced on September 12, 2024, changes in its executive team and board of directors. Specifically, Dr. Elizabeth O'Farrell has been appoint
• UroGen Pharma to be Acquired by Foundry Acquisition — 8-K · 2024-08-15T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. announced on August 14, 2024, that it has entered into a definitive agreement to be acquired by Foundry Acquisition, Inc. The transaction is
• UroGen Pharma Files 8-K on Operations — 8-K · 2024-08-13T00:00:00.000Z [neutral] Risk: low
  UroGen Pharma Ltd. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and
• UroGen Pharma Q2 2024: Assets $614K, Liabilities $65K — 10-Q · 2024-08-13T00:00:00.000Z [neutral] Risk: low
  UroGen Pharma Ltd. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $614,035 and total liabilities of $65,212 for the qu
• UroGen Pharma Appoints New CMO, CCO, and Board Member — 8-K · 2024-08-08T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. announced on August 6, 2024, several key executive and board changes. Dr. Arun Singh has been appointed as Chief Medical Officer, and Ms. Jen
• UroGen Pharma Shareholder Meeting: Director Elections & Equity Plan — DEF 14A · 2024-07-01T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. is holding its 2024 Annual Meeting of Shareholders on August 7, 2024. Shareholders will vote on the election of two Class II directors, Mr. R
• SC 13G Filing — SC 13G · 2024-06-24T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-06-24T00:00:00.000Z [neutral]
• UroGen Pharma Raises $100M in Public Offering — 8-K · 2024-06-18T00:00:00.000Z [bullish] Risk: medium
  UroGen Pharma Ltd. announced on June 17, 2024, the closing of its previously announced underwritten public offering of 10,350,000 ordinary shares, raising appro
• Deciphera to Acquire UroGen Pharma for $755M — 8-K · 2024-06-13T00:00:00.000Z [bullish] Risk: medium
  UroGen Pharma Ltd. announced on June 13, 2024, that it has entered into a definitive agreement to be acquired by Deciphera Pharmaceuticals, LLC. The transaction
• UroGen Pharma Files 8-K for Operations and Financials — 8-K · 2024-05-13T00:00:00.000Z [neutral] Risk: low
  UroGen Pharma Ltd. filed an 8-K on May 13, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exh
• UroGen Pharma Ltd. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-13T00:00:00.000Z [neutral] Risk: low
  UroGen Pharma Ltd. (URGN) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. UroGen Pharma Ltd. reported Q1 2024 results. Raw materials valued at $0.
• SC 13G/A Filing — SC 13G/A · 2024-05-08T00:00:00.000Z [neutral]
• UroGen Pharma Ltd. Files 10-K/A Amendment for Fiscal Year Ended Dec 31, 2023 — 10-K/A · 2024-04-29T00:00:00.000Z [neutral] Risk: low
  UroGen Pharma Ltd. (URGN) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. UroGen Pharma Ltd. filed an amended 10-K report for the fiscal
• UroGen Pharma Files 8-K for Financial Updates — 8-K · 2024-03-14T00:00:00.000Z [neutral] Risk: low
  UroGen Pharma Ltd. filed an 8-K on March 14, 2024, to report on its results of operations and financial condition, as well as to file financial statements and e
• UroGen Pharma Ltd. Files 2023 Annual Report on Form 10-K — 10-K · 2024-03-14T00:00:00.000Z [neutral] Risk: medium
  UroGen Pharma Ltd. (URGN) filed a Annual Report (10-K) with the SEC on March 14, 2024. UroGen Pharma Ltd. filed its 2023 Form 10-K on March 14, 2024. The compan
• UroGen Pharma Files 8-K — 8-K · 2024-03-04T00:00:00.000Z [neutral] Risk: low
  UroGen Pharma Ltd. filed an 8-K on March 4, 2024, to report on Regulation FD disclosures and financial statements. The filing does not contain specific financia
• AbbVie to Acquire UroGen Pharma for $750M — 8-K · 2024-03-01T00:00:00.000Z [bullish] Risk: medium
  UroGen Pharma Ltd. announced on March 1, 2024, that it has entered into a definitive agreement to be acquired by Allergan Aesthetics, an AbbVie company. The tra
• Arkin Amends UroGen Pharma Stake Filing — SC 13D/A · 2024-02-22T00:00:00.000Z [neutral] Risk: low
  Moshe Arkin, through Arkin Communications Ltd., filed an Amendment No. 4 to Schedule 13D for UroGen Pharma Ltd. on February 22, 2024. The filing indicates a cha
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• UroGen Pharma Files 8-K for Reg FD Disclosure, Exhibits — 8-K · 2024-02-07T00:00:00.000Z [neutral]
  UroGen Pharma Ltd. filed an 8-K on February 7, 2024, primarily to disclose information under Regulation FD and to include financial statements and exhibits. Thi